Ongoing myocardial damage relates to cardiac sympathetic nervous disintegrity in patients with heart failure

[1]  I. Kubota,et al.  Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[2]  I. Kubota,et al.  Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. , 2005, Journal of cardiac failure.

[3]  I. Kubota,et al.  Dynamic123I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure , 2004 .

[4]  T. Nakata,et al.  Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  I. Kubota,et al.  Angiotensin‐converting enzyme inhibition improves cardiac fatty acid metabolism in patients with congestive heart failure , 2003, Nuclear medicine communications.

[6]  T. Takano,et al.  Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. , 2002, The American journal of medicine.

[7]  Yasuyuki Nakamura,et al.  Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy , 2002, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[8]  H. Naruse,et al.  Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. , 2002, The American journal of cardiology.

[9]  M. Kinoshita,et al.  Relationship between cardiac 123I-metaiodobenzylguanidine imaging and the transcardiac gradient of neurohumoral factors in patients with dilated cardiomyopathy. , 2001, Japanese circulation journal.

[10]  M. Miyagawa,et al.  Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. , 2001, Japanese circulation journal.

[11]  H. Kishida,et al.  Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. , 1999, The American journal of cardiology.

[12]  W. Abraham,et al.  Hormones and hemodynamics in heart failure. , 1999, The New England journal of medicine.

[13]  P. Merlet,et al.  Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Mcwhir,et al.  Requirement for the heart‐type fatty acid binding protein in cardiac fatty acid utilization , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  F. Recchia,et al.  Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. , 1998, Circulation research.

[16]  T. Nakata,et al.  Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts , 1998, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[17]  Y. Takeishi,et al.  Cardiac sympathetic nervous disintegrity is related to exercise intolerance in patients with chronic heart failure , 1998, Nuclear medicine communications.

[18]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[19]  Y. Takeishi,et al.  ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  K. Murata,et al.  Relation of iodine‐123 metaiodobenzylguanidine myocardial scintigraphy to endomyocardial biopsy findings in patients with dilated cardiomyopathy , 1997, Clinical cardiology.

[21]  D. Kelly,et al.  Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. , 1996, Circulation.

[22]  T. Fukuyama,et al.  Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload. , 1996, Journal of the American College of Cardiology.

[23]  A. Quyyumi,et al.  Cardiac sympathetic nerve function in congestive heart failure. , 1996, Circulation.

[24]  W. Mitsuoka,et al.  Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. , 1995, Journal of the American College of Cardiology.

[25]  W. Hermens,et al.  Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans. , 1994, British heart journal.

[26]  J. Glatz,et al.  Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man , 1992, Molecular and Cellular Biochemistry.

[27]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[28]  P. Merlet,et al.  Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Y. Hirota,et al.  Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. , 1991, Clinical biochemistry.

[30]  W. Woodward,et al.  Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  R. Spielmann,et al.  Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. , 1988, Journal of the American College of Cardiology.

[32]  M. Akers,et al.  Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. , 1988, Circulation.

[33]  W. Beierwaltes,et al.  Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[35]  I. Kubota,et al.  Dynamic 123I-MIBG SPECT reflects sympathetic nervous integrity and predicts clinical outcome in patients with chronic heart failure. , 2004, Annals of nuclear medicine.

[36]  M. Böhm,et al.  Evidence for reduction of norepinephrine uptake sites in the failing human heart. , 1995, Journal of the American College of Cardiology.